Leerink Partnrs Issues Positive Estimate for IDXX Earnings

IDEXX Laboratories, Inc. (NASDAQ:IDXX) – Analysts at Leerink Partnrs boosted their Q2 2025 earnings estimates for IDEXX Laboratories in a research note issued on Monday, April 21st. Leerink Partnrs analyst D. Clark now forecasts that the company will post earnings of $3.23 per share for the quarter, up from their previous forecast of $3.22. The consensus estimate for IDEXX Laboratories’ current full-year earnings is $11.93 per share. Leerink Partnrs also issued estimates for IDEXX Laboratories’ FY2025 earnings at $11.88 EPS.

A number of other research firms also recently weighed in on IDXX. Bank of America raised their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research report on Tuesday, February 4th. Piper Sandler boosted their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research report on Monday, February 10th. Stifel Nicolaus cut their target price on IDEXX Laboratories from $450.00 to $420.00 and set a “hold” rating for the company in a research note on Monday, April 14th. StockNews.com lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 12th. Finally, Barclays upped their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research note on Tuesday, February 4th. Four analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $523.75.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock opened at $440.98 on Thursday. IDEXX Laboratories has a fifty-two week low of $356.14 and a fifty-two week high of $548.88. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. The stock has a market cap of $35.74 billion, a P/E ratio of 41.33, a price-to-earnings-growth ratio of 3.41 and a beta of 1.50. The firm’s fifty day moving average price is $420.16 and its 200-day moving average price is $429.68.

Institutional Investors Weigh In On IDEXX Laboratories

Large investors have recently modified their holdings of the stock. Geode Capital Management LLC boosted its position in IDEXX Laboratories by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 2,297,271 shares of the company’s stock valued at $948,279,000 after acquiring an additional 37,734 shares in the last quarter. Bamco Inc. NY boosted its position in shares of IDEXX Laboratories by 4.3% during the fourth quarter. Bamco Inc. NY now owns 2,005,522 shares of the company’s stock valued at $829,163,000 after purchasing an additional 82,264 shares in the last quarter. Franklin Resources Inc. boosted its position in shares of IDEXX Laboratories by 2.5% during the third quarter. Franklin Resources Inc. now owns 1,412,700 shares of the company’s stock valued at $675,259,000 after purchasing an additional 34,305 shares in the last quarter. Invesco Ltd. grew its stake in IDEXX Laboratories by 6.8% in the fourth quarter. Invesco Ltd. now owns 1,160,988 shares of the company’s stock worth $479,999,000 after purchasing an additional 74,324 shares during the period. Finally, Norges Bank bought a new position in IDEXX Laboratories in the fourth quarter worth $412,258,000. Institutional investors own 87.84% of the company’s stock.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director M Anne Szostak sold 3,000 shares of the firm’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now owns 3,061 shares of the company’s stock, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP George Fennell sold 9,986 shares of the business’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the transaction, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.98% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.